

Price Sensitive Information

The Meeting of the Board of Directors of Beacon Pharmaceuticals PLC held on Wednesday, 28 January 2026 at 3.15 PM at its Corporate Office at Beacon Business Centre, 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka -1223 has approved the Un-audited Half Yearly Financial Statements of the Company for the period ended 31st December 2025 and has taken the following decisions:

1) Financial Information:

Earning Per Share (EPS)	: Tk. 4.73
Net Asset Value Per Share (NAVPS)	: Tk. 32.32
Net Operating Cash Flow Per Share (NOCFPS):	Tk. 6.57

2) The Comparative statement of financial information:

	Jul'25-Dec'25	Jul'24-Dec'24	Oct'25-Dec'25	Oct'24-Dec'24
Earning Per Share (EPS)	Tk. 4.73	Tk. 3.47	Tk. 2.47	Tk. 1.91
Net Operating Cash Flow Per Share (NOCFPS)	Tk. 6.57	Tk. 6.38	-	-
Particulars	As at 31 December 2025		As at 30 June 2025	
Net Asset Value Per Share (NAVPS)	Tk. 32.32		Tk. 28.86	

By the order of the Board of Directors

S/D

Md. Sahabuddin FCS
Company Secretary

BEACON[®]
Pharmaceuticals PLC

BEACON Business Centre:
9/B/2 Toyenbee Circular Road, Motijheel, Dhaka-1223